Terkko Navigator / BioDrugs

Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database

Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States

Administration of CD4 + CD25 high CD127− FoxP3 + Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets

Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients

A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study

Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab

Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders

Acknowledgement to Referees

European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption

Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?

Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study

Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease

European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice

The Immunotherapy Landscape in Renal Cell Carcinoma

Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?

Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials

PF-06410293: An Adalimumab Biosimilar

Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence

Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Monoclonal Antibody-Based Therapies for Myasthenia Gravis

Innovative Therapies for Hemoglobin Disorders

Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date

Correction to: Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study

Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges

Prediction of Immunogenicity of Therapeutic Proteins: Validity of Computational Tools

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

Therapeutic Potential of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Inhibitors in Polycystic Kidney Disease

Application of Glatiramer Acetate to Neurodegenerative Diseases beyond Multiple Sclerosis: The Need for Disease-Specific Approaches

Understanding and Applying Regulatory Guidance on the Nonclinical Development of Biotechnology-Derived Pharmaceuticals

Fibroblast Growth Factor-21 as a Therapeutic Agent for Metabolic Diseases

Selective Targeting of Cancer Stem Cells: A New Concept in Cancer Therapeutics

RNAi Therapy for HIV Infection: Principles and Practicalities

Human Papillomavirus Quadrivalent (types 6, 11, 16, 18) Recombinant Vaccine (Gardasil): Profile Report